Home / Health / Multiple Myeloma Cure Closer: ASH Meeting Shocks
Multiple Myeloma Cure Closer: ASH Meeting Shocks
12 Dec, 2025
Summary
- ASH 2025 showcased unprecedented data for multiple myeloma treatments.
- Johnson & Johnson's TECVAYLI plus DARZALEX showed significant PFS benefit.
- New therapies suggest long-term survival and potential functional cures.
Groundbreaking clinical advances in multiple myeloma treatment were unveiled at the 67th American Society of Hematology (ASH) Annual Meeting held December 6-9, 2025. Leading biopharmaceutical companies presented unprecedented efficacy data, suggesting that long-term disease-free survival, and potentially a 'functional cure,' is within reach for more patients. Novel immunotherapies and targeted agents are reshaping the treatment landscape.
Johnson & Johnson's late-breaking results from the Phase III MajesTEC-3 study highlighted the combination of TECVAYLI and DARZALEX FASPRO. This combination showed the most impressive progression-free survival (PFS) benefit ever seen in a Phase III multiple myeloma trial, with a hazard ratio of 0.17. After three years, 83.4% of patients on this regimen remained alive and progression-free.
The data also revealed high complete response rates of 81.8% and minimal residual disease (MRD)-negative rates of 57.6%. With significantly prolonged overall survival and 91% of patients progression-free at three years, these findings indicate a potential 'functional cure' for relapsed or refractory multiple myeloma patients, heralding a major shift in disease management.
